Abstract # 190:

Scheduled for Monday, August 28, 2017 11:00 AM-11:20 AM: (Grand Ballroom) Oral Presentation


C. N. Ross1,2,3
1Texas A&M University San Antonio, Department of Science and Mathematics, One University Way, San Antonio, TX 78224, USA, 2University of Texas Health San Antonio - Barshop Institute for Longevity and Aging, 3Southwest National Primate Research Center
     Marmosets are an emerging model in which to examine aging and age related disease progression. The talks in the symposium will summarize current knowledge of phenotypic aging as well as the state of the field. There are many other avenues for future research to explore beyond the initial stages of phenotype characterization of aging in the marmosets including the examination of interventional therapies such as drug testing and genetic manipulation. A few cases will be highlighted including the drugs rapamycin and metformin. Rapamycin is an mTOR suppressor which in many ways mimics the effects of caloric restriction in the signaling pathways. The results of its actions include the extension of longevity and healthspan in mouse models. Efficacy testing of rapamycin in marmosets has revealed that the animals tolerate the drug and that there are no obvious detrimental effects. Current and future work hopes to examine the effects of rapamycin on longevity and health in the marmoset. Metformin is a drug that stabilizes blood glucose and general metabolic health and is proposed as a potential anti-aging drug which is being tested in the marmosets. Additionally, researchers are exploring the development of genetic models of disease and disease progression associated with aging in the marmoset. This final talk in the symposium will present what is currently known and the future directions of marmoset translational research.